Appili Therapeutics Inc.
APLI.TO
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 149.20K | 144.10K | 72.00K | 72.00K | 89.50K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 149.20K | 144.10K | 72.00K | 72.00K | 89.50K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 149.20K | 144.10K | 72.00K | 72.00K | 89.50K |
| SG&A Expenses | 1.75M | 1.89M | 1.96M | 2.05M | 1.98M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.53M | 5.49M | 6.45M | 7.33M | 7.37M |
| Operating Income | -4.38M | -5.34M | -6.38M | -7.26M | -7.28M |
| Income Before Tax | -2.07M | -1.78M | -1.63M | -1.91M | -2.90M |
| Income Tax Expenses | 74.00K | 59.90K | 35.40K | 13.10K | 400.00 |
| Earnings from Continuing Operations | -2.14 | -1.84 | -1.66 | -1.92 | -2.90 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.14M | -1.84M | -1.66M | -1.92M | -2.90M |
| EBIT | -4.38M | -5.34M | -6.38M | -7.26M | -7.28M |
| EBITDA | -4.37M | -5.33M | -6.37M | -7.25M | -7.27M |
| EPS Basic | -0.02 | -0.02 | -0.01 | -0.02 | -0.02 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 |
| EPS Diluted | -0.02 | -0.02 | -0.01 | -0.02 | -0.02 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 |
| Average Basic Shares Outstanding | 492.16M | 485.06M | 485.06M | 485.06M | 485.06M |
| Average Diluted Shares Outstanding | 492.16M | 485.06M | 485.06M | 485.06M | 485.06M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |